Ozempic Eligibility for Weight Loss: Understanding the Weight Requirements

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no weight requirement for Ozempic, because Ozempic is not approved for weight loss. The Ozempic prescribing information contains no BMI threshold, no weight-based eligibility criterion, and no weight-management indication anywhere in it. Its three approved indications are all in type 2 diabetes. The BMI numbers people have in mind when they search this question — 30, or 27 with a weight-related condition — belong to a different semaglutide product, Wegovy, which holds the weight-management approval. Getting this distinction right changes what you should be asking a prescriber.

What Ozempic's Label Actually Requires

Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — in adults with type 2 diabetes and established cardiovascular disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Every one of those begins with a diagnosis, not a number on a scale. The gating criterion for Ozempic is type 2 diabetes. A person with a BMI of 42 and no diabetes does not meet the labeled population; a person with a BMI of 24 and type 2 diabetes does. That is the opposite of how the question is usually framed online.

Why People Think There Is a BMI Cutoff

Weight reduction is a well-documented effect of semaglutide, and it was measured throughout the diabetes trial program. But an observed effect is not an indication. An indication is a regulatory statement about the population and purpose for which a sponsor submitted evidence and the FDA agreed the benefit-risk balance was favorable. Weight was a secondary consideration in a program whose primary endpoints were glycemic.

The BMI thresholds circulating in weight-loss discussions come from the obesity trial programs and the labels they supported. Applying them to Ozempic imports criteria from a product with a different application, different trials, and different labeling.

Wegovy Holds the Weight-Management Approval

The Wegovy label is where weight-based eligibility actually lives. Wegovy injection is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. It also carries an indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and an indication in noncirrhotic MASH with moderate to advanced liver fibrosis.

The pediatric criterion in the label's trial description is a BMI corresponding to the 95th percentile or greater for age and sex. For adults, the conventional clinical definitions used in the supporting trials were a BMI of 30 kg/m² or more, or 27 kg/m² or more with a weight-related coexisting condition. Note also that Wegovy now exists in two forms — the injection and Wegovy tablets — and they do not carry an identical set of indications.

The Evidence Bases Are Not Interchangeable

The trials behind each label were designed to answer different questions. STEP 1, the 68-week randomized trial supporting the weight-management approval, reported a mean body weight change of −14.9% with once-weekly semaglutide 2.4 mg versus −2.4% with placebo. That is a trial built to measure weight, in a population enrolled on weight criteria.

The SELECT trial, which studied semaglutide 2.4 mg for cardiovascular outcomes, found a 20% reduction in major adverse cardiovascular events. And Wegovy injection's labeled maximum is no longer 2.4 mg — a 7.2 mg once-weekly maintenance option now sits in the label, supported by the STEP UP program, which reported −18.7% mean weight change at 7.2 mg versus −15.6% at 2.4 mg and −3.9% with placebo over 72 weeks in 1,407 participants. None of those findings appear in Ozempic's label, because they were not submitted as the basis for Ozempic's approvals.

What Actually Determines Eligibility Is Clinical, Not Arithmetic

Even where BMI criteria exist, they are a screen, not a decision. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 — a contraindication that flows from the boxed warning about dose-dependent thyroid C-cell tumors observed in rodents. The label also carries warnings for acute pancreatitis, diabetic retinopathy complications, hypoglycemia when combined with insulin or insulin secretagogues, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation.

Any of those can make a person with a qualifying BMI a poor candidate, and none of them can be assessed from a height and weight. This is why a legitimate intake asks about your history, your other medications, and your labs rather than just running a BMI calculation.

Off-Label Prescribing and Insurance Are Separate Questions

A licensed clinician may prescribe an approved drug outside its labeled indication when they judge it clinically appropriate. That practice is lawful and routine across medicine. What it does not do is change the approval status, create a labeled BMI criterion where none exists, or obligate an insurer to pay.

Coverage frequently keys off the indication rather than the ingredient, which is why a plan may cover one semaglutide product and decline another for the same person with the same body weight. If your question is really "will this be covered," that is a benefits question for your plan, and the answer often turns on diagnosis coding rather than on your BMI.

Where Compounded Semaglutide Fits

Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded preparations for safety, effectiveness, or quality before marketing. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. Because there is no FDA-approved label for a compounded preparation, there is likewise no labeled BMI criterion attached to it — eligibility is a clinical determination made by the prescriber.

That is not a loophole, and it is not a lower bar. It means the assessment is individualized rather than checkbox-driven, and it means the quality of the intake matters more, not less.

Better Questions Than "Do I Qualify?"

Framing eligibility as a threshold to clear invites the wrong conversation. The more useful questions are which product is approved for the outcome you actually want, whether anything in your history rules that product out, what the evidence base behind it looks like in people resembling you, and what the plan is if the response is smaller than the trial averages.

Trial means are not promises. STEP 1's −14.9% average was an average, with substantial spread on either side of it, in participants receiving structured lifestyle support alongside the medication. A prescriber who talks about the distribution rather than the headline number is giving you a more honest basis for a decision than any eligibility calculator can.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is there a BMI requirement for Ozempic?

No. The Ozempic prescribing information contains no BMI threshold and no weight-management indication. Its three approved indications are all in type 2 diabetes: improving glycemic control, reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in chronic kidney disease.

Which semaglutide product is approved for weight loss?

Wegovy. Its label covers reducing excess body weight in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition, combined with a reduced-calorie diet and increased physical activity. Wegovy also carries a cardiovascular risk-reduction indication and an indication in noncirrhotic MASH with moderate to advanced fibrosis.

What BMI numbers apply to Wegovy?

The conventional clinical definitions used in the supporting trials were a BMI of 30 kg/m² or more for obesity, or 27 kg/m² or more with a weight-related coexisting condition. For pediatric patients aged 12 and older, the label's trial description specifies a BMI corresponding to the 95th percentile or greater for age and sex. Your prescriber applies the criteria in the current labeling.

How much weight was lost in the trials?

STEP 1, a 68-week randomized trial, reported a mean body weight change of −14.9% with once-weekly semaglutide 2.4 mg versus −2.4% with placebo. Wegovy's labeled maximum is now higher: the STEP UP program reported −18.7% at 7.2 mg versus −15.6% at 2.4 mg and −3.9% with placebo over 72 weeks in 1,407 participants. None of those results appear in Ozempic's label.

Can Ozempic be prescribed off-label for weight loss?

A licensed clinician may prescribe an approved drug outside its labeled indication when they judge it clinically appropriate, and that is lawful. It does not change the approval status, does not create a labeled BMI criterion where none exists, and does not obligate an insurer to cover it. Coverage often keys off the indication and diagnosis coding rather than off body weight.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.